SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Complete Enrollment in Phase 3 AETHERA Trial of ADCETRIS® for Post-Transplant Patients With Hodgkin Lymphoma